ProKidney Statistics
Total Valuation
ProKidney has a market cap or net worth of $573.64 million. The enterprise value is $307.66 million.
Important Dates
The next estimated earnings date is Monday, May 11, 2026, before market open.
| Earnings Date | May 11, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
ProKidney has 301.92 million shares outstanding. The number of shares has increased by 36.79% in one year.
| Current Share Class | 141.94M |
| Shares Outstanding | 301.92M |
| Shares Change (YoY) | +36.79% |
| Shares Change (QoQ) | +4.45% |
| Owned by Insiders (%) | 17.76% |
| Owned by Institutions (%) | 21.56% |
| Float | 93.67M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 642.37 |
| Forward PS | 849.54 |
| PB Ratio | 1.91 |
| P/TBV Ratio | n/a |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 344.52 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 9.13, with a Debt / Equity ratio of 0.01.
| Current Ratio | 9.13 |
| Quick Ratio | 8.82 |
| Debt / Equity | 0.01 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -41,251.75 |
Financial Efficiency
Return on equity (ROE) is -43.17% and return on invested capital (ROIC) is -29.06%.
| Return on Equity (ROE) | -43.17% |
| Return on Assets (ROA) | -26.56% |
| Return on Invested Capital (ROIC) | -29.06% |
| Return on Capital Employed (ROCE) | -54.13% |
| Weighted Average Cost of Capital (WACC) | 14.40% |
| Revenue Per Employee | $3,866 |
| Profits Per Employee | -$298,641 |
| Employee Count | 231 |
| Asset Turnover | 0.00 |
| Inventory Turnover | n/a |
Taxes
In the past 12 months, ProKidney has paid $414,000 in taxes.
| Income Tax | 414,000 |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +128.92% in the last 52 weeks. The beta is 1.86, so ProKidney's price volatility has been higher than the market average.
| Beta (5Y) | 1.86 |
| 52-Week Price Change | +128.92% |
| 50-Day Moving Average | 2.07 |
| 200-Day Moving Average | 2.39 |
| Relative Strength Index (RSI) | 46.23 |
| Average Volume (20 Days) | 813,745 |
Short Selling Information
The latest short interest is 15.33 million, so 5.08% of the outstanding shares have been sold short.
| Short Interest | 15.33M |
| Short Previous Month | 15.57M |
| Short % of Shares Out | 5.08% |
| Short % of Float | 16.37% |
| Short Ratio (days to cover) | 27.73 |
Income Statement
In the last 12 months, ProKidney had revenue of $893,000 and -$68.99 million in losses. Loss per share was -$0.52.
| Revenue | 893,000 |
| Gross Profit | 893,000 |
| Operating Income | -165.01M |
| Pretax Income | -151.20M |
| Net Income | -68.99M |
| EBITDA | -158.43M |
| EBIT | -165.01M |
| Loss Per Share | -$0.52 |
Full Income StatementBalance Sheet
The company has $270.02 million in cash and $4.04 million in debt, with a net cash position of $265.98 million or $0.88 per share.
| Cash & Cash Equivalents | 270.02M |
| Total Debt | 4.04M |
| Net Cash | 265.98M |
| Net Cash Per Share | $0.88 |
| Equity (Book Value) | 300.79M |
| Book Value Per Share | -7.13 |
| Working Capital | 249.94M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -$120.12 million and capital expenditures -$15.20 million, giving a free cash flow of -$135.31 million.
| Operating Cash Flow | -120.12M |
| Capital Expenditures | -15.20M |
| Depreciation & Amortization | 6.58M |
| Net Borrowing | -26,000 |
| Free Cash Flow | -135.31M |
| FCF Per Share | -$0.45 |
Full Cash Flow StatementMargins
| Gross Margin | 100.00% |
| Operating Margin | -18,477.83% |
| Pretax Margin | -16,931.47% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
ProKidney does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -36.79% |
| Shareholder Yield | -36.79% |
| Earnings Yield | -12.03% |
| FCF Yield | -23.59% |
Analyst Forecast
The average price target for ProKidney is $7.40, which is 289.47% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $7.40 |
| Price Target Difference | 289.47% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 5 |
| Revenue Growth Forecast (5Y) | 228.94% |
| EPS Growth Forecast (5Y) | n/a |
Stock ForecastsFair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
ProKidney has an Altman Z-Score of -1.67. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -1.67 |
| Piotroski F-Score | n/a |
